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Allogeneic stem cell transplantation (allo-SCT) has become an important treatment modal-
ity for patients with high-risk acute myeloid leukemia (AML) and is also under investigation
for soft tissue sarcomas.The therapeutic success is still limited by minimal residual disease
(MRD) status ultimately leading to patients’ relapse. Adoptive donor lymphocyte infusions
based on MRD status using IL -15-expanded cytokine-induced killer (CIK) cells may pre-
vent relapse without causing graft-versus-host-disease (GvHD).To generate preclinical data
we developed mouse models to study anti-leukemic- and anti-tumor-potential of CIK cells
invivo.Immunodeﬁcientmice(NOD/SCID/IL -2Rγc−,NSG)wereinjectedintravenouslywith
humanleukemiccelllinesTHP-1,SH-2andwithhumanrhabdomyosarcoma(RMS)celllines
RH41 and RH30 at minimal doses required for leukemia or tumor engraftment. Mice trans-
plantedwithTHP-1orRH41cellswererandomlyassignedforanalysisofCIKcelltreatment.
Organs of mice were analyzed by ﬂow cytometry as well as quantitative polymerase chain
reaction for engraftment of malignant cells and CIK cells. Potential of CIK cells to induce
GvHD was determined by histological analysis. Tissues of the highest degree of THP-1
cell expansion included bone marrow followed by liver, lung, spleen, peripheral blood (PB),
and brain. RH30 and RH41 engraftment mainly took place in liver and lung, but was also
detectable in spleen and PB. In spite of delayed CIK cell expansion compared with malig-
nant cells, CIK cells injected at equal amounts were sufﬁcient for signiﬁcant reduction of
RH41 cells, whereas against fast-expanding THP-1 cells 250 times more CIK than THP-1
cells were needed to achieve comparable results. Our preclinical in vivo mouse models
showed a reliable 100% engraftment of malignant cells which is essential for analysis of
anti-cancer therapy. Furthermore our data demonstrated that IL -15-activated CIK cells have
potent cytotoxic capacity against AML and RMS cells without causing GvHD.
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INTRODUCTION
Allogeneic stem cell transplantation (allo-SCT) is an established
method in the treatment of high-risk acute leukemia in children
(Bader et al.,2004; Rettinger et al.,2011),and may also play a role
inthetreatmentof high-risksofttissuesarcomainchildren.Espe-
cially patients with primary alveolar rhabdomyosarcoma (RMS)
above the age of 10years with bone or bone marrow (BM) metas-
tases have no realistic chance to survive their disease with conven-
tional treatment (Koscielniak et al., 1997; Klingebiel et al., 2008;
Perez et al., 2011). By evaluating the impact of allo-SCT in both,
leukemiaandsofttissuesarcomapatients,minimalresidualdisease
(MRD) after transplantation is the reason for disease recurrence,
and therefore is the strongest negative effector of the therapeutic
success of allo-SCT. Once a stem cell recipient relapses, further
therapeutic options are limited. For instance, donor lymphocyte
infusion(DLI)isonlyefﬁcaciousforalimitednumberof diseases,
and the high T cell doses required for DLI raise the risk for severe
graft-versus-host-disease (GvHD; Rettinger et al.,2011).
Cytokine-induced killer (CIK) cells are known in principle to
becapableof eradicatingavarietyof bothhematologicalandsolid
malignancies in a non-MHC-restricted manner, without possess-
ing signiﬁcant alloreactive potential (Takayama et al., 2000; Baker
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et al., 2001; Edinger et al., 2003; Kornacker et al., 2006; Sangiolo
et al., 2009; Kim et al., 2007a,b,c). In recent years, the application
of CIKcellshasevolvedfromexperimentalobservationsintoearly
clinical studies (Introna et al., 2007), and CIK cells are now con-
sidered superior to lymphokine-activated killer (LAK) cells and
tumor-inﬁltrating lymphocytes (TIL) for cancer immunotherapy.
In this context, CIK cells exhibit a stronger anti-tumor effect
and continue to differentiate and survive in vivo without mainte-
nance of exogenous cytokines after injection (Olioso et al., 2009).
Activated CIK cells represent a heterogeneous population of poly-
clonal T cells sharing both natural killer (NK) phenotype and
functional properties of NK cells (Pievani et al., 2011). CIK cells
can be efﬁciently expanded in vitro from peripheral blood (PB),
BM mononuclear cells and umbilical cord blood by addition of
interferon (IFN)γ, activating antibody directed against CD3 and
interleukin (IL)-2 (Lu and Negrin, 1994; Thorne et al., 2006). We
recently used IL-15 for further CIK cell activation and expansion
(Rettinger et al., 2012). We could show that IL-15-activated CIK
cells have an increased anti-leukemic potential in vitro compared
to conventional IL-2-activated CIK cells. Furthermore,our modi-
ﬁed protocol allowed us to shorten ex vivo expansion time of CIK
cells. Therefore, in this study we used IL-15-activated CIK cells
after 10days of culture for in vitro and in vivo analyses.
NOD/SCID/IL-2Rγc− (NSG) mice have a phenotype of severe
combined immunodeﬁciency lacking functional T, B, and NK
lymphocytes and, therefore, permit establishment of human
xenografts (Ishikawa et al., 2005; Shultz et al., 2005). Other than
NSG mouse models in many cases lacked reliable engraftment of
malignant cells. A reliable engraftment of malignant cells, best
mimicking engraftment sites of human malignancies is essential
for functional analysis of human cellular therapies in preclinical
animal models.
In this study we focused on the principal biological charac-
teristics and engraftment sites of human acute myeloid leukemia
(AML) and RMS cells injected via the tail vein in sublethally irra-
diated NSG mice. In addition, IL-15-activated day 10 CIK cells
wereinoculatedforfunctionalanalysesregardinganti-tumor,anti-
leukemic and GvHD potential in NSG mice, which had received
grafts of human AML and RMS cells.
MATERIALS AND METHODS
AML AND SOFT TISSUE SARCOMA CELLS
M4 subtype AML cell line, THP-1 was obtained and cultured as
previously described (Rettinger et al., 2012). M2 subtype AML
cell line, SH-2 was purchased from DSMZ (Deutsche Sammlung
von Mikroorganismen und Zellkulturen GmbH, Braunschweig,
Germany) and was maintained in IMDM medium supplemented
with 20% fetal calf serum (FCS), l-glutamine, and antibiotics
(penicillin 100U/mL, streptomycin 100μg/mL) according to the
manufacturer’s instructions. Alveolar RMS RH30, RH41, and
embryonal RMS TE671 cell lines were obtained and cultured as
described (Kuci et al., 2010b). After written informed consent,
primaryEwing’ssarcomacellswereharvestedfromaresectedtho-
racic tumor of a Ewing’s sarcoma patient. The Ewing’s sarcoma
patient was diagnosed with the ﬁrst relapse after allo-SCT. Ewing
sarcoma samples were cryopreserved and subsequently thawed to
be used in the experiments.
GENERATION OF CIK CELLS
The Ethical Review Board of the Medical Faculty of the University
Hospital Frankfurt/Main, Germany approved the study proto-
col to take blood from healthy volunteers after written informed
consent for the purpose of generating cellular therapies against
leukemia and soft tissue sarcomas (Geschäfts-Nr. 298/07). CIK
cells were generated from peripheral blood mononuclear cells
(PBMC) after standard Ficoll separation as previously described
(Rettingeretal.,2012).Inbrief,cellswereresuspendedatadensity
of 3×106 cells/mL in RPMI 1640, supplemented with 10% FCS,
l-glutamine and antibiotics and primed by adding 1000U/mL
IFN-γ on day 0 and 100ng/mL anti-CD3 antibody (MACS GMP
CD3 pure, Miltenyi Biotech, Bergisch Gladbach, Germany) and
500U/mL IL-2 within the following 24h of culture. At day 4
of culture, cell density was adjusted to 1×106 cells/mL. About
500U/mLIL-2or50ng/mLIL-15andculturemediumwereadded
every3days,respectively.CIKcellswereexpandedover10days.On
day 10 of culture CIK cells were harvested and used for analysis.
IN VITRO CYTOTOXICITY ANALYSIS BY EUROPIUM RELEASE ASSAYS
Europium release assay was used for in vitro cytotoxicity analysis
aspreviouslydescribed(Rettingeretal.,2012).Inbrief,targetcells
were labeled with BATDA (Perkin Elmer, Boston, USA) washed
and co-cultured with CIK cells in duplicates or triplicates at an
effector to target cell ratio (E:T ratio) of 20:1 in U-bottom-96-
well culture plates (NUNC,Roskilde,Denmark). Supernatant was
collected from each well and co-incubated with europium solu-
tion (Europium, Perkin Elmer, Turku, Finland) on ﬂat-bottom-
96-well plates (NUNC, Roskilde, Denmark). Fluorescence data
were recorded using a time resolved ﬂuorometer (1420-018 Vic-
tor,Perkin Elmer,Waltham,MA,USA). The percentage of speciﬁc
cytolysiswascalculatedforeachwellasdescribedpreviously(Ret-
tinger et al., 2012), and means with SD were calculated from each
duplicate or triplicate.
ESTABLISHMENT OF MOUSE MODELS FOR HUMAN AML AND RMS
NSG mice were purchased from the Jackson Laboratory (Bar
Harbor, ME, USA) and were maintained in the animal facili-
ties of the University of Frankfurt/Main, Germany under speciﬁc
pathogen-free conditions. The described research was approved
by the Animal Care Committee of Frankfurt am Main University
and the Regierungspräsidium Darmstadt, Germany (Gen. Nr. F.
133/08).
For the establishment of human leukemia and RMS models
in mice, 6- to 8-week old NSG mice were sublethally irradiated
with 200 cGy 24h prior to intravenous (i.v.) injection of AML
or RMS cells (Biobeam 2000, Eckert and Ziegler, Bebig, Ger-
many). Subsequently, mice received tail vein injections of either
1×104 or1×103 THP-1cells.Inparallel,miceweretransplanted
with 5×106,2.5×106,1×106,or 0.5×106 SH-2 cells. For RMS
engraftment, mice were inoculated with 1×106 RH41 cells or
1×105 RH30 cells,respectively.
Animals were euthanized on days 5, 15, 25, 30, 32, and 45 after
transplantationof malignantcells,ormonitoredforsurvival.Mice
showingvisiblesignsofpoorhealthorphysicalabnormalitieswere
sacriﬁced. Mice were sacriﬁced by carbon dioxide asphyxiation
followed by cervical dislocation.
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CIK CELL TREATMENT OF AML OR RMS MICE
In the ﬁrst series of experiments, mice were inoculated i.v. with
the minimal cell dose of 1×104 THP-1 cells and 1×106 RH41
cells sufﬁcient to induce cancer. Randomly selected mice were
injected with 1×106 IL-15-activated day 10 CIK cells 1day after
transplantation of malignant cells.
Inthesecondseriesof experimentsCIKcelldosewasincreased
to2.5×106 cellsandCIKcellswereinoculated24hafterinjection
of 1×104 THP-1 cells into randomly selected mice. THP-1 and
RH41injectedmiceweresacriﬁced25and45daysaftertransplan-
tationofmalignantcellsandorganswereanalyzedforengraftment
of malignant cells.
HARVEST OF HUMAN CELLS FROM ORGANS OF NSG MICE
Cell suspensions of liver, spleen, lung, brain, PB, and BM were
prepared. Brieﬂy, BM cells were collected from each tibia and
femur by ﬂushing bones with culture medium. Mouse erythro-
cytes within BM and PB samples were lysed with lysing buffer
(Mouse Erythrocyte Lysing Kit, R&D Systems, Wiesbaden, Ger-
many) and washed once with washing buffer (Mouse Erythrocyte
Lysing Kit, R&D Systems,Wiesbaden, Germany) according to the
manufacturer’sinstructions.Othercellsuspensionswereprepared
from mouse organs digested by collagenase, ﬁltered through a
100-μM cell strainer and washed with phosphate buffered saline
(PBS). Aliquots of cell suspensions were analyzed by four-color
ﬂowcytometryanalysis(FACS)andquantitativepolymerasechain
reaction (qPCR).
QUANTIFICATION AND CHARACTERIZATION OF HUMAN CELLS IN THE
ORGANS OF NSG MICE BY FACS
Leukemia burden in CIK cell treated and untreated mice were
quantiﬁed by FACS. In addition, CIK cells were characterized by
FACS. Cells were washed once in PBS resuspended in 100μL PBS,
and incubated with ﬂuorescein isothiocyanate (FITC)-,phycoery-
thrin (PE)-, phycoerythrin–cyanin (Cy) 5-, or allophycocyanin
(APC)-conjugated-anti human monoclonal antibodies (mAbs)
for 20min at 4˚C, washed twice in PBS and resuspended in
200μL of PBS. The frequency of human CD45 (FITC, PerCP,
APC, BD Biosciences, Heidelberg, Germany; PE, BD Pharmin-
gen, Heidelberg, Germany), CD3 (PE, PerCP, BD Biosciences;
APC, BD Pharmingen), CD4 (FITC,APC, BD Pharmingen), CD8
(FITC, PE, BD Biosciences; APC, BD Pharmingen), CD25 (PE,
BD Pharmingen), CD56 (FITC, PE, BD Biosciences; APC, BD
Pharmingen), TCRαβ (PE, Miltenyi Biotec, Bergisch Gladbach
Germany), TCRγδ (FITC, BD Biosciences), and CD33 (PerCP,
BD Biosciences) expressing cells was analyzed. Isotype-matched
ﬂuorochrome-conjugated IgGs were used as controls. After gat-
ing on viable cells, data on 5×105 events were acquired by ﬂow
cytometer BD FACSCalibur (BD Biosciences) using Cell Quest
software (BD Biosciences).
QUANTIFICATION AND DISCRIMINATION OF HUMAN CELLS IN THE
ORGANS OF NSG MICE BY PCR
DNA PCR was performed from cell suspensions as previously
described(Kucietal.,2010a).Inbrief,genomicDNAwasextracted
using the QIAamp blood and tissue kit (Qiagen, Hilden, Ger-
many). As a ﬁrst step a quantitative real time PCR approach
was used to assess the amount of human cells of each tissue
sample by speciﬁc ampliﬁcation of the human albumin gene
(Pongers-Willemse et al., 1999). As a standard was used the serial
dilution preparation of human DNA in mouse DNA. For each
reaction 50ng DNA were processed and the assay was able to
detect one human cell beneath 1000 murine cells. As a second
step within the human cell fraction proportion of CIK and tumor
cells were discriminated by human speciﬁc STR-genotyping simi-
lartochimerismanalyses(Scharf etal.,1995).Informativelocifor
the discrimination of THP-1 and CIK cells were D7S820 and for
the discrimination of RH41 and CIK cells D3S1358, D13S317,
and D18S51, respectively. Leukemia or tumor burden of each
mouse was obtained by adding leukemia or tumor signals per
analyzed organ. Primers and probes were achieved from Euroﬁns
(Euroﬁns MWG GmbH, Ebersberg, Germany) and genotyping
was performed using the STR multiplex PCR system Powerplex16
(Promega GmbH,Mannheim,Germany).
HISTOLOGY
Histologicalanalysiswasperformedbymfddiagnostics(mfddiag-
nosticsGmbH,Wendelsheim,Germany).Tissuewasﬁxedin100%
bufferedformalin,parafﬁnembedded,sectioned,andstainedwith
hematoxylin–eosin (HE). Microscopy analysis was performed by
mfd diagnostics using Zeiss AXIO Imager A1/M1.
STATISTICAL ANALYSIS
ResultswerecomparedusingthepairedStudent’stwotailedt-test.
A p-value <0.05 was considered to be signiﬁcant.
RESULTS
IN VITRO CYTOTOXICITY OF CIK CELLS
Our previous studies demonstrated that IL-15-activated CIK cells
in part were superior in killing of leukemia cells compared with
IL-2-stimulated CIK cells (Rettinger et al., 2012). This study was
performed, to conﬁrm these ﬁndings against a variety of sarcoma
c e l l s .A f t e r1 0d a y so fin vitro culture IL-15-stimulated CIK cells
and conventional IL-2-stimulated CIK cells were added to tar-
get cells at an E:T ratio of 20:1 and tested in europium release
assays. Target cells used were TE671, RH30, primary Ewing’s
sarcoma and RH41 cells. Interestingly, IL-15 activation resulted
in signiﬁcantly increased cytotoxicity against TE671 (p <0.0237,
Figure 1A), RH30 (p <0.0123, Figure 1B), and primary Ewing’s
sarcoma cells (p <0.0154,Figure1C) compared to IL-2-activated
CIK cells. In vitro cytotoxicity of IL-15-stimulated CIK cells was
not increased against RH41 cells (Figure 1D). Altogether, IL-15-
stimulationwasvastlydifferentamongtheindividualcelllinesand
was equivalent of IL-2-stimulation in RH41 cells in vitro.
ESTABLISHMENT OF HUMAN AML AND RMS MODELS IN NSG MICE
We suggested that IL-15-activated CIK cells may have differential
effects in vivo compared with our in vitro ﬁndings, and there-
fore may also be effective against RH41 and THP-1 cells in vivo,
which both were equivalent killed by IL-2- and IL-15-activated
CIKcells(Rettingeretal.,2012).BesidesRH41andTHP-1models,
we established additional xenotransplant models of both tumor
entities, AML and RMS, in immunodeﬁcient NSG mice. Taking
intoconsiderationtheexcellentproliferativecapacityofAMLcells,
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FIGURE 1 | Increased cytotoxic potential of IL-15-stimulated
cytokine-induced killer cells against sarcoma cells. Cytotoxicity of
IL -15-stimulated and conventional IL -2-stimulated CIK cells after 10days
of culture against embryonal rhabdomyosarcoma (RMS) cell lineTE671
(A), alveolar RMS cell lines RH30 (B) and RH41 (D), and primary
Ewing’s sarcoma cells (C) was analyzed by europium release assay
in vitro. Mean values from three independent experiments are shown.
IL -15-activated CIK cells exhibited a signiﬁcantly increased cytotoxicity
againstTE671 (p <0.0237), RH30 (p <0.0123) and primary Ewing’s
sarcoma cells (p <0.0154) compared to IL -2-activated CIK cells.
Cytotoxicity of IL -15-activated CIK cells was not increased against RH41
cells (D).
we performed dose-ﬁnding experiments to determine the mini-
mal AML dose required for a delayed, but reliable engraftment of
human AML cells. The determined cell dosage differed markedly
between cell lines, and was 1×104 in case of fast-expanding
THP-1 cells (manufacturer’s instructions:doubling time,35–50h;
Figure 2A) and 0.5×106 in case of slowly expanding SH-2 cells
(manufacturer’s instructions: doubling time, 80h; Figure 2B).
However, despite injection of a minimum of THP-1 cells, mice
showed physical abnormalities within 24–34days after injection,
whereas mice injected with a minimum of SH-2 cells developed
symptoms within a period of 82–103days post-transplant. Fur-
ther analyses of organs of affected mice showed that most of the
THP-1engraftmenttookplaceintheBM,butwasalsodecreasingly
detectableinlung,spleen,liver,PB,andbrain(Figure2C).Theear-
liest time point for PCR-based detection of THP-1 engraftment
within analyzed organs (BM, PB, liver, spleen, lung, and brain)
taken together was 15days after transplantation. From then, cells
expanded dramatically 665-fold (day +15,0.20; day +32,132.95)
within a period of 17days (Figure 2D).
According to their proliferative capacity, 1×105 of RH30 cells
(manufacturer’s instructions: doubling time, 35h) and 1×106 of
RH41 cells (manufacturer’s instructions: doubling time, 24–36h)
were found to be sufﬁcient for tumorigenesis. RMS engraftment
of RH30 and RH41 cells was monitored at days +15, +30 and
>+45 post-transplant. Engraftment of RH30 cells in BM, PB,
liver, spleen, and lung taken together was detectable 15days after
transplantation (Figure3A),and RH30 injected mice,which were
observed for survival, became ill 48–69days after injection. Most
of the RMS engraftment took place within the reticuloendothelial
system (RES) of the liver (Figures 3B,C), but was also detectable
to a decreasing extent in lung, BM, spleen, and PB (Figure 3D).
PCRresultsdemonstratedthatRH30cellsexpanded627-fold(day
+15, 0.21; >day +45, 131.71; Figure 3A). RH41 signals within
analyzed compartments (BM, PB, liver, spleen, and lung) taken
t o g e t h e rw e r ed e t e c t e da td a y+15 (Figure 3E), and RH41 mice,
which were observed for survival,showed signs of discomfort 45–
51days after transplantation. Expansion rate of RH41 cells,which
were injected at higher cell doses compared with RH30 cells was
18020-fold(day+15,0.01;>day+45,180.20)within30daysafter
RMS engraftment (Figure 3E). Most of the RH41 engraftment
tookplaceinliverandlung,butwasalsodetectabletoadecreasing
extent in BM, PB, and spleen (Figures 3F,G).
IN VIVO CYTOTOXICITY OF IL-15-STIMULATED CIK CELLS AGAINST RMS
Having established the xenotransplant tumor models,we assessed
thecytotoxicityof IL-15-activatedCIKcellsafter10daysof exvivo
culture against RH41 cells in vivo. With regard to clinical trans-
latability, RH41 cells were used best mimicking resistant tumor
cells. NSG mice were sublethally irradiated and transplanted with
1×106 RH41 cells. About 1×106 CIK cells were injected in one
part of RH41-transplanted mice 24h after tumor cell injection.
CIK cell treated mice and untreated controls were analyzed for
RMS engraftment 45days after injection of RH41 cells. Gross
examination of organs was equivalent in CIK cell treated and
untreated mice. PCR-based results conﬁrmed that small numbers
of injected CIK cells were able to migrate to sites where tumor
wasfound(Figure4A).Furthermore,theseCIKcellswerecapable
of signiﬁcantly reducing RH41 burden by comparing compart-
mentsofCIKcelltreatedmice(Figure4A)withuntreatedcontrols
(Figure4B) where RH41 cells were detectable. Results of analyzed
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FIGURE 2 | Establishment of humanized acute myeloid leukemia
mouse models. Preclinical AML models were established in
immunodeﬁcient NSG mice. Results from three independent experiments
are shown. Minimal cell doses required for AML engraftment were 1×10
4
in case ofTHP-1 cells (A) and 0.5×10
6 in case of SH-2 cells (B). Mice
injected with a minimum ofTHP-1 cells showed disease development
within 24–34days (A). Mice injected with a minimum of SH-2 cells
developed disease within 82–103days (B). PCR-based detection of human
albumin showed that most of theTHP-1 engraftment occurred in the bone
marrow (BM), but was also detectable at decreasing amounts in lung,
spleen, liver peripheral blood (PB), and brain (C).THP-1 engraftment within
bone marrow (BM), peripheral blood (PB), liver, spleen, lung, and brain
taken together increased by 665-fold (day +15, 0.20; day +32, 132.95)
within 17days (D).
compartments taken together conﬁrmed that CIK cell treatment
(n =3) resulted in a signiﬁcantly reduced tumor burden com-
paredwiththeuntreatedcontrols(n =5;controlgroup,180±104;
treatment group, 67±6,p <0.001; Figure 4C).
IN VIVO CYTOTOXICITY OF IL-15-STIMULATED CIK CELLS AGAINST AML
Cytotoxicity of IL-15-stimulated day 10 CIK cells was determined
in THP-1-injected mice 25days after transplantation. Previously
analyzed, fast-expanding THP-1 cells (Rettinger et al., 2012)w e r e
used in this study best representingAML engraftment in patients.
Groups of mice inoculated with 1×104 THP-1 cells were injected
with different doses of CIK cells. To this end,1×106 or 2.5×106
CIK cells were transplanted via the tail vein in THP-1-injected
mice. Despite aggressive expansion of THP-1 cells, PCR-based
resultsdemonstratedthatCIKcellswerecapableofreducingTHP-
1burdeninallanalyzedcompartments(BM,PB,liver,spleen,lung,
and brain) taken together. Furthermore,our results demonstrated
that cytotoxicity of CIK cells was dose-dependent (untreated con-
trolgroup,161±56;treatmentgroups,1×106 CIKcells,74±56;
2.5×106 CIK cells, 43±35, p <0.0001, Figure 5A). In this series
of experiments, chimerism analysis was used to determine THP-
1 and CIK cell signals in BM, liver, spleen, lung, brain, and PB
of mice (Figure 5B). Comparable results were obtained by FACS
analysisofBMsamplesofCIKcelltreatedmiceanduntreatedcon-
trols (Figure 5C). Here, THP-1 cells were quantiﬁed by staining
withhumananti-CD45andanti-CD33antibodies.Engraftmentof
THP-1 cells (CD45+CD33+) and CIK cells (CD45+CD33−) was
negatively correlated and THP-1 engraftment was even inhibited
in two out of seven mice injected with 2.5×106 CIK cells
(Figure 5C). THP-1 engraftment was markedly reduced but not
inhibited after injection of 1×106 CIK cells. This might be due
to the fact that compared to THP-1 expansion,CIK cell expansion
was delayed and CIK cells (CD45+) were not detectable within
30days post-transplant like shown by anti-CD45 staining within
organs of representative examples after injection of 1×106 CIK
c e ll so n l y( Figure5D). FACS analysis of organs of THP-1-injected
mice treated with 2.5×106 CIK cells (CD3+) conﬁrmed that
CIK cells inﬁltrated leukemia sites, resulting in a reduction or
even elimination of CD33+ expressing THP-1 cells (Figure 5E).
In this analysis CIK cells were detected by staining them with a
human anti-CD3 antibody whereas THP-1 cells were quantiﬁed
by staining with a human anti-CD33 antibody.
CIK CELL PHENOTYPE AND POTENTIAL TO INDUCE GvHD
Flow cytometric analysis revealed that CIK cells at the time of
injection displayed a CD3+CD56− rather than CD3+CD56+ or
CD3−CD56+ phenotype (Figure 6A). These T cells expressed
CD8andCD25ratherthanCD4molecules(Figure6A).BManaly-
sesofcancer-inﬁltratingCIKcellsinvivoexclusivelydemonstrated
aCD3+CD56− Tcellphenotype(Figure6B).Inaddition,mostof
theseTcellsexpressedCD4ratherthanCD8antigens(Figure6B).
Graft-versus-host-diseasetargetedtissueslikethegastrointesti-
nal tract, liver, and spleen were analyzed in terms of xenogenic
GvHD mediated by CIK cells. Histological analyses of gut, liver,
andspleenof onerepresentativemouse,withthehighestdegreeof
CIK cell expansion (mouse no. 7,Figures5B,E) demonstrated no
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FIGURE 3 | Establishment of humanized rhabdomyosarcoma mouse
models. Results from three independent experiments demonstrated that
intravenous injection of 1×10
5 RH30 cells was sufﬁcient for
tumorigenesis. PCR-based detection of human albumin in bone marrow
(BM), peripheral blood (PB), liver, spleen, and lung taken together showed
that RH30 cells engrafted by day +15 and expanded 627-fold within
30days (A). Most of the RH30 engraftment occurred within the
reticuloendothelial system (RES) of the liver as shown by HE-staining of
one representative histological analysis (B), but was also detectable to a
decreasing extent in lung, bone marrow (BM), spleen, and peripheral blood
(PB) (C,D). In parallel, injection of 1×10
6 RH41 cells was sufﬁcient for
engraftment of tumor cells. RH41 signals within analyzed compartments
(BM, PB, liver, spleen, and lung) were detectable at day +15 and increased
by 18020-fold within 30days (E). Most of RH41 engraftment occurred in
liver and lung like shown by one representative example (F), but was also
detectable in bone marrow, blood, and spleen (G).
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FIGURE 4 | In vivo cytotoxicity of IL-15-stimulated cytokine-induced killer
cells against rhabdomyosarcoma. CIK cell treated (n=3) and untreated
controls (n=5) among RH41-transplanted mice were analyzed 45days after
transplantation of malignant cells. Chimerism analyses of one representative
example within the treatment group showed that CIK cells were detectable in
the liver spleen and lung (A). RH41 engraftment was most pronounced in liver
and lung, but was also seen to a lesser extent in the bone marrow (BM) and
spleen like shown by one representative untreated control (B). PCR results
from all analyzed organs of the treatment and control group (untreated mice,
n=5; CIK cell treated mice, n=3) taken together showed, that CIK cells were
able to signiﬁcantly reduce tumor growth when compared to untreated mice
[p <0.001, (C)].
or mild xenogenic GvHD potential of IL-15-stimulated CIK cells
(Figure 6C).
DISCUSSION
The aim of this study was to evaluate the efﬁcacy of ex vivo
expanded, IL-15-activated day 10 CIK cells against AML and sar-
coma cells in vivo in an optimized preclinical mouse model with
the goal of clinical translatability. We therefore established a dis-
ease model for AML and sarcoma cells in NSG mice injected via
the tail vein with a minimal leukemic or tumorigenic dose. The
feasibilityandefﬁcacyof infusedCIKcellsinAMLandRMSbear-
ing mice was then analyzed in terms of regression of malignant
cells or alloreactivity of CIK cells.
Transplantation of human AML cells into different strains of
immunodeﬁcientmicehasledtopreclinicalmodelsusedtoinves-
tigate AML and sarcoma biology, and efﬁcacy of immunotherapy
(BonnetandDick,1997;Hudsonetal.,1998;Vormooretal.,2001;
Ito et al., 2002; Feuring-Buske et al., 2003; Meyerrose et al., 2003;
Ishikawa et al.,2005; Kawano et al.,2005; Shultz et al.,2005,2007;
Siegler et al., 2005). NSG mice have been investigated as mod-
els to generate human hematopoiesis in a murine host (Ito et al.,
2002; Shultz et al., 2005). The IL-2Rγc-chain deﬁciency in NSG
mice, also lacking functional B cells and T cells, impairs signal-
ing through multiple cytokine receptors, which block NK cell
development resulting in additional defects in innate immunity
(Shultz et al., 2005, 2007). Agliano et al. (2008) observed a fast
development of leukemia-related symptoms and a high percent-
ageof leukemiacellsinblood,BM,andspleenof intraperitoneally
(i.p.) injected non-irradiated NSG mice. Total body irradiation
in SCID mutant mice was reported to increase radiosensitivity,
associatedwithsomeunpredictablemousemortality(Shultzetal.,
2007).Inaddition,recentreportsshowedasigniﬁcantengraftment
of human cells and a prolonged life span in non-irradiated NSG
mice (Nakamura et al.,2005;Watanabe et al.,2007). Despite these
observations,to best mimic conditioning prior to transplantation
in humans,we decided to irradiate the animals before injection of
human cells. Our results showed that tail vein injection of human
AML and RMS cells resulted in a 100% engraftment of trans-
planted cells. We found that doses of 1×104–1×106 cells per
mouse were sufﬁcient to obtain with certainty leukemia or sar-
coma engraftment within 3–8weeks. We suggested that the log
difference in cell requirement may depend on the proliferative
capacity and migration characteristics of injected cells. As one
reason, cell requirement was less in fast-expanding AML subtype
M4 cells,and more in slowly expandingAML subtype M2 or RMS
cells. We observed most of the leukemia engraftment in the BM,
and most of the RMS engraftment in liver and lung. The RES of
liver and lung usually represents with plenty of microvasculature,
and velocity of blood ﬂow inside is slow. Hence, it appears likely
that infused RMS cells, which are larger than AML cells, were
retained at these sites. In contrast to our ﬁnding, that 0.5×106
i.v. injected SH-2 cells were sufﬁcient for leukemic engraftment
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FIGURE 5 |Anti-leukemic activity of IL-15-stimulated cytokine-induced
killer cells. Mice were inoculated i.v. with the minimal leukemic dose of
1×10
4 THP-1 cells. About 1×10
6 and 2.5×10
6 CIK cells were transplanted
via the tail vein into one part of mice injected withTHP-1 cells. Bone marrow
(BM), peripheral blood (PB), liver, spleen, lung, and brain were analyzed for
THP-1 and CIK cell engraftment by PCR 25days after transplantation of
malignant cells. Results of analyzed compartments taken together showed
that CIK cell treatment resulted in a markedly decreasedTHP-1 engraftment
compared with the untreated controls (A). Reduction of leukemia burden was
dose-dependent. Chimerism analysis was used to distinguish between AML
and CIK cells. Chimerism results like shown here by one representative
example [mouse no. 7 , 1×10
4 THP-1 cells and 2.5×10
6 CIK cells, (B)]
demonstrated that CIK cells were detectable in analyzed organs. Except the
brain,THP-1 signals were not detectable in CIK cell inﬁltrated organs. Bone
marrow results obtained by ﬂow cytometry, conﬁrmed that CIK cells
(CD45
+CD33
−) were capable of reducing AML (CD45
+CD33
+) engraftment in
a dose-dependent manner (C). Representative examples of mice injected
with 1×10
6 CIK cells (CD45
+) only, demonstrated that CIK cells expanded as
early as 30days post-transplant (D).Therefore, expansion of 1×10
6 injected
CIK cells was delayed compared withTHP-1 engraftment. Flow cytometry
analysis from seven independent experiments within the treatment group
which were performed 25days afterTHP-1 injection conﬁrmed that CIK cells
(CD3
+) injected at higher doses (2.5×10
6 CIK cells) were capable of reducing
or even eliminating AML (CD33
+) engraftment (E).
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FIGURE 6 | Phenotype and alloreactive potential of cytokine-induced
killer cells. Before injection, CIK cells were CD3
+CD56
− or CD3
+CD56
+
rather than CD3
+CD56
+ like shown by FACS analyses of three independent
examples (A). Most of theseT cells expressed CD8 and CD25 rather than
CD4 antigens (A). Cytometric analysis of injected CIK cells from seven
independent bone marrow samples within the treatment group demonstrated
predominantly a CD3
+CD56
− T cell phenotype (B). Most of theseT cells were
CD4
+ rather than CD8
+ (B). Histological analysis from one representative CIK
cell treated mouse with the best CIK cell engraftment (mouse no. 7 ,
Figures 5B,E,1×10
4 THP-1 cells+2.5×10
6 CIK cells) showed no xenogenic
GvHD in classical GvHD targeted tissues like gut and liver as well as in
spleen, the preferred homing sites of CIK cells (C).
in NSG mice, other groups reported that 1×107 subcutaneously
(s.c.) or i.v. injected SH-2 cells were needed for engraftment in
5/8BALB/cnudemiceand4/10SCIDmice8weeksafterinjection
(Qiuetal.,2008).Wesuggestthatapreclinicalmodelwithreliable
engraftment rates is essential for analysis of cellular therapy.
Adoptive cellular immunotherapy is an important treatment
to eliminate residual leukemia or tumor cells after allo-SCT. Over
the past 20years the development of CIK cell immunotherapy
for the treatment of hematological and solid malignancies has
received considerable attention. CIK cells are capable of a broad
MHC-unrestricted anti-leukemic and anti-tumor activity as doc-
umentedbothinvitro andinvivo inmurinemodels(Schmidtwolf
et al.,1991,1994;Lu and Negrin,1994;Hoyle et al.,1998;Sweeney
et al., 1999; Alvarnas et al., 2001; Baker et al., 2001;Verneris et al.,
2001; Edinger et al., 2003). Limited data are available on the efﬁ-
cacy of CIK cells against solid tumors (Scheffold et al., 2002;
Wang et al., 2002; Helms et al., 2010; Sangiolo, 2011). In previous
work we modiﬁed CIK cell generation by using IL-15 for CIK cell
activation (Rettinger et al., 2012). IL-15 activation signiﬁcantly
enhanced CIK cell-mediated cytotoxicity against leukemia cells
invitro,whereasthealloreactivepotentialof IL-15-stimulatedCIK
cells remained low. Furthermore, we could show that IL-15 acti-
vation can minimize the culture period prior to adoptive transfer
without affecting the in vitro efﬁcacy of CIK cells. Hence, IL-15-
stimulation may change the outcome of CIK cell generation from
terminally differentiated and potentially exhausted day 21 CIK
cells to day 10 CIK cells with a more naïve phenotype and potent
proliferative capacity.
In our experiments, mice received grafts of human AML and
RMS cells. In order to demonstrate that IL-15-activated CIK cells
have differential effects in vivo, rather than in vitro, and to best
mimicclinicalsituationsof high-riskpatients,RH41cellsresistant
to FAS- and TRAIL-induced apoptosis (Petak et al., 2000, 2003)
andfast-expandingTHP-1cells,whichwerepreviouslytested(Ret-
tinger et al.,2012) were used as targets for in vivo analysis. TRAIL
is important for CIK cell-mediated induction of apoptosis (Kuci
etal.,2010b).Therefore,TRAIL-resistanceof RH41cellsmayhave
inﬂuenced in vitro cytotoxicity of IL-15-activated CIK cells in this
study.
Experimental mice were then assigned randomly to different
treatment groups, and were infused with equal amounts of CIK
cells in the RMS setting,and 100–250 times increased amounts of
CIK cells compared with injected malignant cells in the leukemia
setting. To avoid non-engraftment of leukemia and tumor cells
by co-transplantation of CIK cells, CIK cells were injected at
least 24h after administration of malignant cells. We observed
that i.v. injection of 2.5×106 or 1×106 CIK cells resulted in a
strong inhibition of AML and sarcoma growth. Hereby CIK cells
were capable of reducing AML engraftment in a dose-dependent
manner after being injected within 24h after administration of
malignant cells. This time point might represent MRD status,
and might therefore be optimal for MRD-directed preemptive
immunotherapy. An excess of leukemia/tumor cells will likely
not be overcome by immunological measures. Furthermore, our
study results demonstrated, that CIK cells widely distributed to
manyorgansthroughthebloodstream.Itwaspreviouslyreported
that CIK cells migrated to tumor sites within 7h after injection,
and remained detectable at these sites for an additional 9days
(Verneris et al., 2000; Edinger et al., 2003; Skitzki et al., 2004;
Kornacker et al., 2006). Our results revealed the presence of con-
siderable numbers of CIK cells in different compartments up to
51dayspost-transplant.But,CIKcellmovementviathebloodcir-
culation and CIK cell expansion at tumor sites depended on the
number of CIK cells infused. Some reports showed that CIK cells
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ﬁrst entered into the lung, after inoculation of nude mice (Hazel-
rigg et al., 2002; Kim et al., 2009), peaked there within 2–6h after
injection,then declined,and re-distributed to organs such as liver,
spleen,and kidney within 24h.Another report demonstrated that
CIK cells infused via the tail vein homed directly to the RES (Li
et al., 2011). In contrast, in our study aggregation and expansion
of infused CIK cells mostly occurred in BM and spleen at the time
of analysis.
Cytokine-inducedkillercellpopulationsundergoamaturation
process during ex vivo expansion. During this process we could
show in previous studies that CIK cell subpopulations arise with a
maximumof anti-tumoractivityandproliferativecapacitywithin
day 7–14 of culture (Kuci et al.,2010b; Rettinger et al.,2012). Ter-
minallydifferentiatedeffectorCD3+CD56+ Tcellsubpopulations
are known to possess potent cytotoxicity, but have low prolifera-
tive capacity (Wajchman et al., 2004; Powell et al., 2005). On the
other hand, CD3+CD56− cells, which represent early effector T
cells, exhibit reduced cytotoxicity but a higher capacity for prolif-
eration, home to lymphoid tissues, and persist in vivo (Gattinoni
et al., 2005). Therefore the entire expanded CIK cell population
may represent an ideal cell population for adoptive immunother-
apy.TheCD3+CD56+ subsetcoulddeliverpotentcytotoxicityfor
the immediate destruction of malignant cells while the less potent
CD3+CD56− cell subset could proliferate and persist in vivo for
a longer duration and therefore provide a continuous source of
cells with long term cytotoxic activity. In addition, the small
CD3−CD56+ NK cell subset has been shown to efﬁciently lyse
MHC class I-deﬁcient tumor targets that escape T cell recogni-
tion. The spleen is known to be the best organ to detect T cells,
whereas NK cells are best detectable in BM (Varga et al.,2010). At
the time of inoculation most of CIK cells showed CD3+CD56−
followed by CD3+CD56+ and CD3+CD56− phenotype. Most of
CD3+CD56− CIK cells expressed CD8 and CD25 rather than
CD4 molecules. After injection we detected CD3+CD56− but no
CD3+CD56+ or CD3−CD56+ cells at the time of analysis. In
addition we demonstrated that persisting CD3+CD56− cells were
CD4+ rather than CD8+, suggesting that the phenotype of CIK
cells at the time of adoptive transfer reverted without cytokine
stimulation in vivo and resulted in an expansion of CD3+CD4+
CIK cells in vivo.
It was shown that adoptive transfer of allogeneic CIK cells in
a murine model caused minimal GvHD-like symptoms as CIK
cells inﬁltrated GvHD targeted tissues to a lesser degree and more
transiently than conventional T cells (Baker et al., 2001; Verneris
et al., 2001; Beilhack et al., 2005; Nishimura et al., 2008). Irradi-
ated Balb/c mice tolerated up to 20×106 day 14 CIK cells which
caused minimal GvHD whereas as few as 2.5×106 splenocytes,
a saTc e l le q u i v a l e n ti nm i c e ,i n d u c e da c u t el e thal GvHD. As one
reason,CIKcellsshowedaslowerdivisionrate,highersusceptibil-
ity to apoptosis, increased IFNγ release, and reduced expression
of homing molecules (Duffner et al., 2003; Welniak et al., 2004;
Nishimuraetal.,2008).IFNγhasaprotectiveeffectagainstGvHD
at early time points after transplantation. Homing molecules and
chemokine receptors direct alloreactive cells toward GvHD tar-
getedinﬂamedtissues.Irradiationinducedtissueinﬂammationin
our experimental setting. However, we observed only mild tissue
damage in mice when infused CIK cells persisted and expanded at
these sites. Affected mice showed minimal weight loss, and were
somewhat hunched and scrubby.
In conclusion,human CIK cells trafﬁc and survive in a murine
recipient for prolonged periods of time with minimal xenogenic
GvHD. CIK cells retain strong anti-leukemia and anti-tumor
activity and homing capacity to leukemia and tumor sites. There-
fore, CIK cells may be an effective alternative to prevent or treat
leukemiaorsarcomarelapseafterallo-SCT.Fromourﬁndings,we
expectthattheMRDstatewillbemostsusceptibletoimmunother-
apy.ThereforediagnosticsforMRDandpreemptiveimmunother-
apy using CIK cells to prevent relapse in patients with leukemia or
sarcoma should be considered early after allo-SCT.
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